A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
Atopic Dermatitis: Phase 3 double-blinded study, 8-week study with potential rollover into an open label extension. Topical cream. Currently enrolling males/females 2-17 years old with atopic dermatitis (AD), also known as eczema Eczema is an inflammatory skin condition that can occur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up. The purpose of this study is to find out if the investigational study medicine, tapinarof cream, can help with the treatment of AD.
For this study there are up to 7 visits and 2 phone calls over a period of 13 weeks. Subjects will use a topical cream every day for 8 weeks and will come to the study site for questionnaires, physical exams, blood draws, and urine testing at multiple visits.
Compensation for travel and expenses may be available
AD covering between 5% and 35% body surface area
Willing to follow all study guidelines
Certain treatments for AD are not allowed; coordinator will discuss specific treatments